



PRESS RELEASE

May 28, 2024

Ziccum partners with Dagens Industri for Investor Relations program

Ziccum partners with Dagens Industri, the largest Nordic business paper, to improve shareholders' access to news updates and raise broader awareness of its continuous scientific and commercial progress.

Ziccum AB has signed a partnership with the Investor Relations arm of Dagens Industri, joining a select group of Nordic SMEs in a bid to ensure timely, efficient, and professional dissemination of its increasing information flow. The scope includes interviews in text and video format as well as company coverage in smaller and larger features in the main DI paper.

Operating at the cutting edge of science, developing a disruptive technology enabling new and much improved biopharmaceuticals and continuously gaining increased recognition from international Pharma & Biotech industry, Ziccum sees the need to keep its loyal regional investor base well-apprised by providing systematic and accessible updates on its progress. Ziccum could not ask for a better partner than Dagens Industri, an institution of business reporting among the Nordic investment community for decades.

Ziccum's CEO, Ann Gidner: "Now that Dagens Industri are selecting a few smaller Swedish listed companies to be well featured, we are delighted to be included and it is perfect timing with our need for better visibility in investors' circles".

About Dagens Industri:

Dagens Industri was founded in 1976 and is currently owned by the Swedish media group Bonnier AB. DI's online edition, di.se, has been consistently voted as Sweden's "best economics online site" for 20 years (from 1999 to 2019) in a competition held by the PR firm Hallvarsson & Halvarsson.

For more information about Ziccum, please contact:

Ann Gidner,
CEO Ziccum
Mail: gidner@ziccum.com
Mobile: +46 722140141

Fredrik Sjövall,
Chairman of the Board, Ziccum AB
Mail: sjovall@ziccum.com
Mobile: +46 706 45 08 75

Ziccum's Certified Adviser is
Carnegie Investment Bank AB (publ).
Follow us on <https://eucaps.com/ziccum>

About Ziccum

Ziccum is developing LaminarPace™, a unique drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. The technology is offered by licensing to vaccine and biologics developers and manufacturers in the global pharmaceutical industry. By reducing drying stress to the active ingredient, LaminarPace™ uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and are highly suitable for novel administration routes. The technology has been successfully applied to mRNA, peptides, proteins, antibodies, lipids and enzymes as well as excipients and adjuvants, and is well suited for industrial application. Ziccum is listed on the Nasdaq First North Growth Market.

Attachments

[Ziccum partners with Dagens Industri for Investor Relations program](#)